

Contents

Part I Introduction

1 General Description	3
1.1 Introduction.....	3
1.2 Incidence and Prevalence.....	5
1.3 Predisposing and Genetic Factors.....	8
References.....	16
2 Natural History: Importance of Size, Site, Histopathology	19
2.1 Natural History.....	19
2.2 Influence of Site	19
2.3 Staging	19
2.4 Staging of Retroperitoneal and Visceral Sarcoma	27
2.5 Prognostic Factors for Extremity and Superficial Soft Tissue Sarcoma.....	30
2.6 Disease-Specific Survival.....	31
2.7 Prognostic Factors for Survival Following Local Recurrence of Extremity Sarcoma	32
2.8 AJCC Staging.....	33
2.9 Prognostic Factors—Nomograms	38
References.....	39
3 General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy	41
3.1 Extent of Primary Surgery	41
3.2 Surgical Treatment of Local Recurrence	43
3.3 Diagnostic Imaging.....	43
3.4 Surgery for Metastatic Disease	45
3.4.1 Pulmonary Metastasis	45
3.4.2 Surgery and Management of Sarcoma Liver Metastasis	50

3.5	Radiation Therapy.....	51
3.5.1	Adjuvant Radiation Therapy	53
3.5.2	Types of Radiation Therapy	54
3.5.3	Dose/Volume of Radiation Therapy	56
3.5.4	Morbidity of Adjuvant Radiation Therapy.....	57
3.5.5	Definitive Radiation Therapy	59
3.6	Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas	59
3.6.1	Sarcomas More Common in Adults	59
3.6.2	Larger Randomized Studies	60
3.6.3	Selected Meta-analyses of Randomized Trials of Adjuvant Chemotherapy	62
3.6.4	Adjuvant Therapy for GIST	63
3.6.5	Sarcomas More Common in the Pediatric Setting	64
3.7	Brief Comments Regarding Chemotherapy for Metastatic Soft Tissue Sarcoma	65
3.8	Special Techniques for Primary and Locally Recurrent Disease	66
3.8.1	Intra-arterial Chemotherapy	66
3.8.2	Limb Perfusion and Hyperthermia.....	67
3.9	Immunotherapy for Sarcomas.....	68
	References.....	69

Part II Management by Histopathology

4	Gastrointestinal Stromal Tumors	77
4.1	Imaging	77
4.2	Familial GIST	79
4.3	Natural History.....	81
4.4	Diagnosis, Molecular Pathology	83
4.5	Treatment	84
4.6	Adjuvant Imatinib for Primary GIST.....	84
4.7	Neoadjuvant Therapy for Primary Disease Not Amenable to Surgery.....	88
4.8	Treatment of Recurrence.....	89
4.9	First Line Imatinib: For Metastatic GIST	89
4.10	Dose Intensity Over Time	94
4.11	Imatinib Pharmacokinetics.....	95
4.12	Second Line Sunitinib for Imatinib-Resistant Metastatic GIST....	96
4.13	Regorafenib in Third Line for Metastatic GIST	97
4.14	Other Tyrosine Kinase Inhibitors for Metastatic GIST Failing Imatinib and Sunitinib	97
4.15	Newer Agents for GIST	98

References.....	100
5 Liposarcoma	105
5.1 Imaging.....	109
5.2 Diagnosis.....	111
5.3 Treatment.....	111
5.4 Radiation Therapy for Liposarcoma.....	115
5.5 Systemic Therapy: General Considerations.....	117
5.6 Adjuvant Therapy.....	117
5.7 Treatment of Metastatic Disease.....	118
5.8 Outcomes.....	121
5.9 Outcome Following Metastasis.....	122
References.....	123
6 Leiomyosarcoma	125
6.1 Imaging.....	125
6.2 Diagnosis, Molecular Pathology.....	128
6.3 Primary Treatment.....	131
6.4 Radiation Therapy.....	131
6.5 Systemic Therapy.....	132
6.5.1 Adjuvant Chemotherapy for Leiomyosarcoma.....	132
6.6 Outcomes After Primary Therapy.....	132
6.7 Patterns of Recurrence.....	133
6.7.1 Treatment of Recurrence.....	136
6.8 Metastatic Disease.....	136
References.....	139
7 Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma (MFH) and Myxofibrosarcoma) ..	143
7.1 Imaging.....	143
7.2 Diagnosis, Molecular Pathology.....	145
7.3 Natural History.....	145
7.4 Treatment.....	146
7.5 Radiation Therapy.....	146
7.6 Metastatic Disease.....	146
7.7 Adjuvant Chemotherapy.....	148
7.8 Outcome.....	148
References.....	150
8 Synovial Sarcoma	153
8.1 Imaging.....	153
8.2 Diagnosis, Molecular Pathology.....	153
8.3 Treatment.....	156
8.4 Radiation Therapy.....	156
8.5 Chemotherapy.....	157
8.6 Treatment of Recurrence.....	158

8.6.1	Local Recurrence	158
8.7	Systemic Treatment.....	159
8.8	Outcome	161
	References.....	162
9	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor	165
9.1	Presentation.....	165
9.2	Imaging	167
9.3	Diagnosis, Pathology	167
9.4	Neurofibromatosis Type 1 and Outcome	170
9.5	Treatment	170
9.6	Radiation Therapy.....	171
9.7	Chemotherapy for MPNST	172
9.8	Outcome	173
	References.....	175
10	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis)	177
10.1	Clinical Presentation	179
10.2	Imaging	179
10.3	Diagnosis, Molecular Pathology	179
10.4	Natural History.....	182
10.5	Treatment	182
10.6	Treatment of Recurrence.....	183
10.7	Systemic Therapy.....	183
10.8	Treatment by Observation.....	185
10.9	Radiation Therapy.....	185
10.10	Patterns of Failure	187
10.11	Outcome	188
	References.....	192
11	Solitary Fibrous Tumor/Hemangiopericytoma	195
11.1	Doege–Potter Syndrome	196
11.2	Primary Therapy	198
11.3	Systemic Therapy for Metastatic Disease.....	198
11.4	Outcome	199
	References.....	200
12	Fibrosarcoma and Its Variants	203
12.1	Outcome	203
12.2	Dermatofibrosarcoma Protuberans.....	203
12.2.1	Outcome.....	207
12.3	Low-Grade Fibromyxoid Sarcoma (Also Termed Evans Tumor).....	209
12.3.1	Outcome.....	212
12.4	Sclerosing Epithelioid Fibrosarcoma.....	213

12.5	Inflammatory Myofibroblastic Tumor.....	214
12.6	Infantile Fibrosarcoma	215
12.7	Myxoinflammatory Fibroblastic Sarcoma/Inflammatory Myxohyaline Tumor of Distal Extremities	216
12.8	Adult-Type Fibrosarcoma	217
	References.....	218
13	Vascular Sarcomas	221
13.1	Epithelioid Hemangioendothelioma	221
13.2	Angiosarcoma/Lymphangiosarcoma.....	224
13.3	Outcome	231
13.4	Kaposi Sarcoma	232
	References.....	234
14	Epithelioid Sarcoma	237
14.1	Outcome.....	240
	References.....	240
15	Sarcomas More Common in Children	243
15.1	Soft Tissue Sarcomas More Commonly Observed in Pediatric Patients.....	243
15.2	Ewing Sarcoma Family of Tumors	244
15.3	Demographics	248
15.4	Primary Therapy	249
15.5	Adjuvant Chemotherapy	250
15.6	High-Dose Systemic Therapy for Metastatic Disease	251
15.7	Standard Cytotoxic Chemotherapy After Disease Relapse	252
15.8	Investigational Approaches.....	253
15.9	Ewing Sarcoma-Like Small Blue Round Cell Tumors	254
15.10	Rhabdomyosarcoma.....	256
15.11	Demographics	256
15.12	Molecular Biology	259
15.13	Risk Stratification.....	261
15.14	Staging	261
15.15	Imaging	262
15.16	Primary Therapy	263
15.17	Chemotherapy for Metastatic Disease	265
15.18	Mesenchymal Chondrosarcoma.....	267
15.19	Embryonal Sarcoma.....	267
	References.....	269
16	Radiation-Induced Sarcoma	275
	References.....	281
17	Alveolar Soft Part Sarcoma	283
17.1	Imaging	283
17.2	Diagnosis, Molecular Pathology	283

17.3	Primary Treatment	286
17.4	Treatment of Metastatic Disease	287
17.5	Outcome	287
	References	288
18	Clear Cell Sarcoma/Melanoma of Soft Parts	291
18.1	Imaging	291
18.2	Diagnosis, Molecular Pathology	291
18.3	Treatment	294
18.4	Outcome	295
	References	296
19	Desmoplastic Small Round Cell Tumor	299
19.1	Imaging	299
19.2	Diagnosis	299
19.3	Treatment	300
19.4	Outcome	303
	References	303
20	Extraskelletal Myxoid Chondrosarcoma	307
20.1	Imaging	307
20.2	Diagnosis	307
20.3	Treatment	309
20.4	Outcome	311
	References	312
21	Other Uterine Sarcomas	315
21.1	Low Grade Endometrial Stromal Sarcoma	315
21.1.1	Diagnosis	316
21.1.2	Treatment	317
21.1.3	Outcome	318
21.2	High Grade Endometrial Stromal Sarcoma	318
21.2.1	Outcome	320
21.3	Undifferentiated Uterine Sarcoma (UUS)	320
21.4	PEComas	321
21.5	Uterine Carcinosarcomas and Other Malignant Mixed Müllerian Tumors	321
21.6	Outcome	323
	References	325
22	Extraskelletal Osteogenic Sarcoma	327
22.1	Imaging	327
22.2	Diagnosis	327
22.3	Treatment	328
22.4	Outcome	331
	References	334

23 Sustentacular Tumors of Lymph Tissue..... 335

23.1 Follicular Dendritic Cell Tumor and Interdigitating Reticulum Cell Tumor 335

23.2 True Histiocytic Sarcoma..... 337

23.3 Langerhans Cell Tumors..... 338

23.4 Outcome..... 339

References..... 341

24 Uncommon/Unique Sites 343

24.1 Heart and Great Vessels 343

24.2 Primary Sarcomas of the Breast..... 344

24.2.1 Phyllodes Tumor 347

24.3 Head and Neck..... 349

24.3.1 Treatment 349

24.4 Primary Sarcomas of the Mediastinum..... 350

24.5 Liver..... 351

References..... 351

Part III Benign and Less Aggressive Lesions

25 Mostly Benign/Rarely Metastasizing..... 355

25.1 Ossifying Fibromyxoid Tumor 355

25.2 Perivascular Epithelioid Cell Tumor (PEComa) and Related Entities, Lymphangiomyomatosis, Angiomyolipoma, Sugar Cell Tumor..... 356

25.3 Therapy 357

25.4 Giant Cell Tumor of Tendon Sheath/Pigmented Villonodular Synovitis 359

25.5 Myoepithelial Tumors of Soft Tissue..... 361

25.6 Glomus Tumor 362

References..... 366

26 Selected Benign Tumors 369

26.1 Lipoma 369

26.2 Lipomatosis..... 370

26.3 Lipoblastoma/Lipoblastomatosis 371

26.4 Angiolipomas..... 371

26.5 Angiomyolipoma 371

26.6 Angiomyelolipoma 373

26.7 Hibernoma..... 373

26.8 Elastofibroma 375

26.9 Granular Cell Tumors 377

26.10 Hemangioma..... 377

26.11 Leiomyoma 380

26.12 Schwannoma..... 380

26.13 Neurofibroma 381

26.14	Myxoma	381
26.15	Angiomyxoma.....	382
26.16	Angiofibroma	382
	References.....	385
27	Reactive Lesions	387
27.1	Myositis Ossificans	387
27.2	Nodular Fasciitis	387
27.3	Sarcoma Masquerade	388
	References.....	390
	Index	391



<http://www.springer.com/978-3-319-41904-6>

Management of Soft Tissue Sarcoma

Brennan, M.; Antonescu, C.; Alektiar, K.; Maki, R.

2016, XVI, 399 p. 338 illus., 234 illus. in color.,

Hardcover

ISBN: 978-3-319-41904-6